Scientific Research Publishing

Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa ()

Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa Guillain-Barré Syndrome (GBS) is the most frequent cause of acute ...

Zenocutuzumab--zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma

Zenocutuzumab--zbco, marketed as BIZENGRI (R), received Breakthrough Therapy Designation from the FDA in October 2025 and was granted accelerated approval in December 2024 for adults with advanced ...

Royal Stoke 'missed opportunity' before death of ex-teacher

RIP Neil ...

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic ...

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and ...
Deccan Chronicle

Excise Constable Soumya Remains Critical: Battling Multiple Organ Failure At NIMS

Soumya is in the respiratory intensive care unit. Doctors said her liver function had deteriorated rapidly within two days ...

SynAct Pharma AB: SynAct Pharma initiates Phase 2 study in respiratory insufficiency

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initia ...

N.J. med spas are in crisis. Sudden law change leaves some fighting to survive.

It's not just Botox and IV therapy. The reversal of a COVID rule could upend family and maternal care, mental healthcare ...
Nursing in Practice

NICE approves first targeted treatment for uncontrolled COPD

NICE has approved the first targeted treatment for chronic obstructive pulmonary disease (COPD), offering a new option to up ...
The National Institute for Health and Care Excellence

New hope for people with breathing condition, COPD, as NICE approves innovative treatment

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines, today announced interim data from a phase 1b study of ABX1100 ...
Medscape

EMA Backs First Therapy for Rare Genetic Muscle Disease

The EMA’s positive opinion on Kygevvi marks a turning point for patients with TK2d, an ultra-rare genetic muscle disease previously managed only with supportive care.